March 2024 Newsletter
Welcome to the March Cresset newsletter where we share our latest results for GPCR benchmarks using Flare™ FEP, Cresset wins ...
News
The Flare V6 release delivers new features, including enhanced 3D graphics and:
Request an evaluation of Flare.
Serious bacterial infections represent a worldwide threat, due mainly to the emergence of antibiotic-resistant bacteria for which there are limited therapies. Research from the University of Cambridge highlighted inhibition of an E. coli enzyme as a plausible route to reduce pathogenicity and increase effectiveness in UTIs.
In recent years, minimizing time-to-market has been prioritized above all else. When you choose to collaborate with Cresset Discovery, you get flexible access to a varied and experienced team, including medicinal and computational chemists, to accelerate your drug discovery projects.
Ignite™ is a new technology to enable rapid 3D virtual screening in combinatorial chemical spaces. The Ignite 3D descriptor uses Cresset field technology which describes a molecule through its spatial extent of electrostatics and its shape for a given conformation. Apply Ignite to your project by outsourcing to Cresset Discovery.
Last few places available for in-person attendance to celebrate the life and work of Andy Vinter, founder of Cresset. Places are still available for virtual attendance but must be booked in advance.
Learn how to develop and implement an appropriate virtual screening strategy for complex target systems using Blaze™, directly, or through our comprehensive modeling platform, Flare.
Learn about our latest developments coming in the Flare V6 release.
Register for 'new features in flare v6'
Opportunity for a Senior Computational Chemistry Developer to assist in developing new scientific techniques and turning these into industry-leading easy-to-use
software products.